Stock listing
NASDAQ:JAZZ Jazz Pharmaceuticals plc Stock
Home listing (NASDAQ) of Jazz Pharmaceuticals plc
Follow Jazz Pharmaceuticals plc into a list and get an email when it puts out news.
Share price · NASDAQ:JAZZ
$230.26 USD -17.51 (-7.1%)
Close on Nov 20, 2026
- Day range
- $227.95 – $238.59 USDNov 20, 2026
- Volume
- 984,644 sharesNov 20, 2026
- Market cap
- $14.95B USDAt the close on Nov 20, 2026 · price × 64.91M shares outstanding
- 52-week range
- $156.95 – $266.38 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $207.2M USDMedian day 740,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:JAZZ · Home | $230.26 USD | -17.51 (-7.1%) | 984,644 | $236.00 | $238.59 | $227.95 | $247.77 | Close on Nov 20, 2026 |
| Frankfurt:J7Z | €209.20 EUR | -5.50 (-2.6%) | — | €209.70 | €213.70 | €209.20 | €214.70 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:JAZZ · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $230.26 | -17.51 | -7.1% | $236.00 | $238.59 | $227.95 | 984,644 | |
| $247.77 | +7.06 | +2.9% | $240.34 | $248.17 | $240.10 | 721,463 | |
| $240.71 | +0.94 | +0.4% | $239.63 | $242.38 | $237.85 | 499,452 | |
| $239.77 | -1.78 | -0.7% | $243.30 | $244.61 | $238.94 | 490,227 | |
| $241.55 | +1.18 | +0.5% | $241.77 | $243.25 | $235.89 | 496,700 | |
| $240.37 | -7.87 | -3.2% | $248.80 | $249.97 | $239.67 | 584,272 | |
| $248.24 | +2.81 | +1.1% | $245.77 | $248.97 | $243.76 | 592,829 | |
| $245.43 | +1.885 | +0.8% | $243.55 | $246.47 | $240.77 | 576,699 | |
| $243.55 | +8.785 | +3.7% | $236.00 | $244.37 | $235.14 | 885,894 | |
| $234.76 | +7.44 | +3.3% | $226.66 | $237.76 | $226.12 | 886,982 | |
| $227.32 | -7.34 | -3.1% | $233.20 | $233.80 | $227.05 | 670,555 | |
| $234.66 | +4.92 | +2.1% | $233.23 | $234.67 | $228.45 | 899,031 | |
| $229.74 | +15.30 | +7.1% | $225.37 | $234.78 | $218.53 | 1,680,855 | |
| $214.44 | -1.54 | -0.7% | $215.84 | $218.36 | $213.81 | 1,037,126 | |
| $215.98 | +8.15 | +3.9% | $209.63 | $216.38 | $209.36 | 1,212,681 | |
| $207.83 | +2.77 | +1.4% | $207.00 | $211.32 | $205.73 | 773,557 | |
| $205.06 | -1.72 | -0.8% | $204.38 | $206.77 | $202.30 | 816,104 | |
| $206.78 | +1.08 | +0.5% | $206.31 | $207.67 | $204.04 | 605,810 | |
| $205.70 | -8.30 | -3.9% | $215.29 | $216.43 | $205.11 | 969,992 | |
| $214.00 | -0.65 | -0.3% | $213.09 | $215.35 | $211.49 | 560,601 | |
| $214.65 | +2.68 | +1.3% | $211.38 | $215.24 | $210.26 | 783,806 | |
| $211.97 | -1.79 | -0.8% | $213.75 | $215.13 | $211.53 | 695,908 | |
| $213.76 | +5.33 | +2.6% | $209.89 | $215.55 | $208.98 | 663,267 | |
| $208.43 | -1.80 | -0.9% | $209.60 | $210.57 | $206.71 | 716,947 | |
| $210.23 | -4.19 | -2.0% | $214.25 | $214.78 | $208.15 | 636,700 | |
| $214.42 | +4.77 | +2.3% | $212.19 | $217.57 | $212.19 | 886,400 | |
| $209.65 | -0.74 | -0.4% | $210.34 | $215.66 | $209.36 | 891,300 | |
| $210.39 | -6.36 | -2.9% | $216.86 | $216.86 | $209.34 | 812,600 | |
| $216.75 | -1.67 | -0.8% | $218.90 | $221.99 | $216.57 | 739,600 | |
| $218.42 | -4.03 | -1.8% | $221.79 | $227.00 | $213.20 | 1,288,300 | |
| $222.45 | -8.74 | -3.8% | $228.55 | $229.33 | $214.68 | 1,268,600 | |
| $231.19 | -0.20 | -0.1% | $229.62 | $235.54 | $227.00 | 578,900 | |
| $231.39 | -4.65 | -2.0% | $236.40 | $236.40 | $228.70 | 862,200 | |
| $236.04 | +0.37 | +0.2% | $235.51 | $238.87 | $234.12 | 844,600 | |
| $235.67 | +2.66 | +1.1% | $233.40 | $237.77 | $231.70 | 636,600 | |
| $233.01 | +1.49 | +0.6% | $230.33 | $234.47 | $229.85 | 740,600 | |
| $231.52 | -0.83 | -0.4% | $231.60 | $236.00 | $230.39 | 1,001,900 | |
| $232.35 | -5.93 | -2.5% | $236.30 | $238.00 | $229.16 | 777,200 | |
| $238.28 | +0.33 | +0.1% | $235.67 | $238.83 | $234.63 | 788,300 | |
| $237.95 | +1.67 | +0.7% | $239.12 | $239.12 | $235.66 | 1,129,600 | |
| $236.28 | +1.40 | +0.6% | $235.82 | $236.52 | $232.00 | 551,300 | |
| $234.88 | -5.69 | -2.4% | $239.26 | $241.33 | $231.59 | 792,200 | |
| $240.57 | -0.89 | -0.4% | $242.01 | $243.21 | $239.78 | 482,000 | |
| $241.46 | +0.72 | +0.3% | $240.87 | $244.49 | $238.53 | 499,200 | |
| $240.74 | -3.10 | -1.3% | $244.55 | $244.55 | $238.98 | 2,214,700 | |
| $243.84 | +0.25 | +0.1% | $246.59 | $247.31 | $243.57 | 569,600 | |
| $243.59 | +2.76 | +1.1% | $242.93 | $244.36 | $241.76 | 602,200 | |
| $240.83 | -5.04 | -2.0% | $246.81 | $246.81 | $239.84 | 702,600 | |
| $245.87 | +0.07 | 0.0% | $247.68 | $248.45 | $244.66 | 465,400 | |
| $245.80 | +5.32 | +2.2% | $244.60 | $246.73 | $244.04 | 422,900 | |
| $240.48 | -0.83 | -0.3% | $240.94 | $244.46 | $239.29 | 1,029,500 | |
| $241.31 | +1.24 | +0.5% | $238.38 | $241.44 | $236.00 | 424,500 | |
| $240.07 | -6.74 | -2.7% | $240.00 | $244.71 | $239.11 | 467,900 | |
| $246.81 | -0.76 | -0.3% | $246.00 | $249.00 | $244.75 | 321,900 | |
| $247.57 | +2.00 | +0.8% | $246.92 | $248.91 | $241.87 | 507,600 | |
| $245.57 | +1.86 | +0.8% | $244.00 | $248.07 | $241.02 | 1,155,900 | |
| $243.71 | -6.97 | -2.8% | $250.13 | $252.50 | $243.02 | 1,072,800 | |
| $250.68 | +6.14 | +2.5% | $241.39 | $252.72 | $241.39 | 1,221,000 | |
| $244.54 | -6.56 | -2.6% | $249.48 | $250.64 | $244.49 | 1,192,900 | |
| $251.10 | +1.81 | +0.7% | $250.00 | $252.85 | $246.99 | 4,740,300 | |
| $249.29 | -10.94 | -4.2% | $257.40 | $259.83 | $248.52 | 2,373,000 | |
| $260.23 | +5.76 | +2.3% | $256.36 | $266.38 | $254.59 | 1,560,100 | |
| $254.47 | +0.19 | +0.1% | $253.66 | $254.70 | $250.44 | 419,900 | |
| $254.28 | +5.58 | +2.2% | $248.75 | $255.85 | $248.55 | 516,600 | |
| $248.70 | -3.46 | -1.4% | $249.60 | $254.93 | $245.76 | 439,900 |
- Ticker
- NASDAQ:JAZZ
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 3, 2026
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Latest earnings call · Nov 2, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2026 Earnings Call
Replay and transcript
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 27 slides
Latest news
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 3, 2026
Closed $234.66 (+2.1%) on Nov 4, 2026
Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
Nov 2, 2026
Closed $229.74 (+7.1%) on Nov 3, 2026
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
Nov 2, 2026
Closed $214.44 (-0.7%) on Nov 2, 2026
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Oct 23, 2026
Closed $214.00 (-0.3%) on Oct 23, 2026
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Oct 19, 2026
Closed $213.76 (+2.6%) on Oct 20, 2026
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Sep 15, 2026
Closed $240.83 (-2.0%) on Sep 15, 2026
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
Aug 31, 2026
Closed $250.68 (+2.5%) on Aug 31, 2026
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
Aug 27, 2026
Closed $251.10 (+0.7%) on Aug 27, 2026
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
Aug 26, 2026
Closed $249.29 (-4.2%) on Aug 26, 2026
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Aug 10, 2026
Closed $256.52 (0.0%) on Aug 10, 2026
Jazz Pharmaceuticals plc on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 36 in the last 12 months · 273 in all · newest Nov 3, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Nov 2, 2026
- Decks
- 37 decks · latest September 2026
Where Jazz Pharmaceuticals plc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:JAZZ · Home listing · This page | NASDAQ | United States | USD |
| Tradegate:J7Z | Tradegate | Germany | EUR |
| gettex:J7Z | gettex | Germany | EUR |
| LS Exchange:A1JS1K | LS Exchange | Germany | EUR |
| Frankfurt:J7Z | Frankfurt | Germany | EUR |
| Lang & Schwarz:A1JS1K | Lang & Schwarz | Germany | EUR |
| BOATS:JAZZ | BOATS | United States | USD |
| Milan:1JAZZ | Milan | Italy | EUR |
| B3:J2AZ34 | B3 | Brazil | BRL |
| BMV:JAZZN | BMV | Mexico | MXN |
| Stuttgart:J7Z | Stuttgart | Germany | EUR |
| BIVA:JAZZN | BIVA | Mexico | MXN |
| BX Swiss:J7Z | BX Swiss | Switzerland | CHF |
| Dusseldorf:J7Z | Dusseldorf | Germany | EUR |
| Hamburg:J7Z | Hamburg | Germany | EUR |
| Hanover:J7Z | Hanover | Germany | EUR |
| Munich:J7Z | Munich | Germany | EUR |
| Xetra:J7Z | Xetra | Germany | EUR |
Valuation
P/E 72.6× against a median of 41.4×: 8th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $18.48B USD
- P/E
- 72.6×
- EV/sales
- 3.9×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 3.6×
- Gross margin
- Not reported
- Operating margin
- 9.0%
- Net margin
- 4.4%
- Debt to equity
- 1.3×
- Beta vs S&P 500
- 0.64
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc · NASDAQ:JAZZ | US$14.95B | US$18.48B | 72.6× | 3.9× | n/a | 3.6× | 4.4% | 1.3× | 0.64 |
| Innovent Biologics, Inc. · HKEX:1801 | US$17.82B | US$15.17B | 146× | 7.8× | 75.9× | 5.7× | 6.2% | 0.1× | n/a |
| Yunnan Baiyao Group Co. Ltd. Class A · SZSE:000538 | US$15.07B | US$13.10B | 19.4× | 2.0× | n/a | 2.5× | 12.2% | 0.0× | n/a |
| Ipsen SA · EURONEXT:IPN | US$14.62B | US$13.51B | 30.0× | 3.4× | 11.2× | 2.8× | 12.1% | 0.2× | n/a |
| Laurus Labs Ltd. · NSE:LAURUSLABS | US$13.38B | US$13.66B | 92.5× | 16.2× | 53.2× | 20.5× | 17.1% | 0.4× | n/a |
| Zydus Lifesciences Limited · NSE:ZYDUSLIFE | US$12.92B | US$13.86B | 28.6× | 4.2× | 17.9× | 4.3× | 13.8% | 0.5× | n/a |
| Elanco Animal Health Incorporated · NYSE:ELAN | US$12.87B | US$15.85B | n/a | 3.1× | 13.1× | 1.9× | −2.9% | 0.5× | 1.20 |
| Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY | US$12.50B | US$12.45B | 41.4× | 3.5× | 22.6× | 3.0× | 8.5% | 0.2× | n/a |
| Cipla Ltd · NSE:CIPLA | US$12.34B | US$11.26B | 39.5× | 3.7× | 21.6× | 3.2× | 10.4% | 0.0× | n/a |
| Mankind Pharma Ltd. · NSE:MANKIND | US$11.88B | US$12.18B | 49.1× | 7.3× | 27.7× | 6.3× | 14.6% | 0.3× | n/a |
| Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. Class A · SSE:600436 | US$11.62B | US$11.29B | 58.9× | 9.5× | n/a | 5.5× | 16.7% | 0.0× | n/a |
| Median of the others | US$12.89B | US$13.31B | 41.4× | 4.0× | 22.1× | 3.8× | 12.1% | 0.2× | 1.20 |
Forecasts
13 strong buy · 7 buy · 2 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 297.50 USD · Analysts' mean
- EPS, year to Dec 2026
- 14.90 · 20 analysts
- Revenue, year to Dec 2026
- 4.81B · 21 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Renee Gala | President and Chief Executive Officer, Jazz Pharmaceuticals plc |
| Heather Ann McSharry | Director, International Airlines Group |
| Laura Hamill | Director, BB Biotech, Fate Therapeutics Inc., and Unchained Labs |
| Patrick G. Enright | Managing Director, Longitude Capital |
| Patrick Kennedy | Director, Jazz Pharmaceuticals plc |
| Seamus Mulligan | Director, Jazz Pharmaceuticals plc |
| Ted W. Love | Director, Jazz Pharmaceuticals plc |
| Thomas Riga | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Bruce C. Cozadd | Chairperson, Jazz Pharmaceuticals plc |
| Norbert G. Riedel | Chairperson, Eton Pharmaceuticals, Inc. |
| Jennifer E. Cook | Director |
| Mark D. Smith | Professor, University of California, San Francisco and Director, Teladoc Health, Inc. and Phreesia, Inc. |
| Renee Gala | President and Chief Executive Officer, Jazz Pharmaceuticals plc |
| Rick E Winningham | Lead Independent Director, Jazz Pharmaceuticals plc |
Events
Calls
| Call | When | Status |
|---|---|---|
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2026 Earnings Call | Mon, Nov 02, 2026 · 4:30 PM ET | Replay |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2026 Earnings Call | Mon, Aug 03, 2026 · 4:30 PM ET | Replay |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2026 Earnings Call | Tue, May 05, 2026 · 4:30 PM ET | Replay |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Q4 2025 Earnings Call | Tue, Feb 24, 2026 · 4:30 PM ET | Replay |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:30 PM ET | Replay |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 4:30 PM ET | Replay |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Q1 2025 Earnings Call | Tue, May 06, 2025 | Replay |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Q4 2024 Earnings Call | Tue, Feb 25, 2025 · 3:30 PM ET | Replay |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 4:30 PM ET | Replay |
| Jazz Pharmaceuticals (NASDAQ:JAZZ) Q2 2024 Earnings Call | Wed, Jul 31, 2024 · 4:30 PM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 2, 2026 · After close | +7.1% |
| Q2 2026 | Aug 3, 2026 · After close | +4.0% |
| Q1 2026 | May 5, 2026 · After close | +7.7% |
| Q4 2025 | Feb 25, 2026 | +8.7% |
| Q3 2025 | Nov 5, 2025 · After close | −2.3% |
| Q2 2025 | Aug 5, 2025 · After close | −6.4% |
| Q1 2025 | May 6, 2025 · After close | −8.8% |
| Q4 2024 | Feb 25, 2025 · After close | +3.2% |
| Q3 2024 | Nov 6, 2024 · After close | +6.8% |
| Q2 2024 | Jul 31, 2024 · After close | +3.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 1, 2024 · After close | −0.9% |
| Q4 2023 | Feb 28, 2024 · After close | −8.3% |
| Q3 2023 | Nov 8, 2023 · After close | −9.1% |
| Q2 2023 | Aug 9, 2023 · After close | +1.6% |
| Q1 2023 | May 10, 2023 · After close | +0.4% |
| Q4 2022 | Mar 1, 2023 · After close | +2.7% |
| Q3 2022 | Nov 9, 2022 · After close | +7.1% |
| Q2 2022 | Aug 3, 2022 · After close | −0.3% |
| Q1 2022 | May 4, 2022 · After close | −2.7% |
| Q4 2021 | Mar 1, 2022 · After close | +12.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 27 slides | September 2026 |
| Corporate Update (August 2026) | Corporate update | 23 slides | Aug 25, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 25 slides | Aug 3, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 29 slides | Feb 24, 2026 |
| Investor Presentation (January 2026) | Investor deck | 39 slides | Jan 9, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference (January 2026) | Conference | 18 slides | January 2026 |
| Q3 2025 Earnings Presentation | Earnings | 24 slides | Nov 5, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 27 slides | Feb 25, 2025 |
| 43rd Annual J.P. Morgan Healthcare Conference 2025 | Conference | 27 slides | Jan 13, 2025 |
| 42nd Annual J.P. Morgan Healthcare Conference (January 2024) | Conference | 31 slides | Jan 8, 2024 |
All 37 decks
Financings
| Raise | Date |
|---|---|
| 1.875% exchangeable senior notes due 2032 Made bigger: US$1.1B Use of proceeds: General corporate purposes | Aug 27, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.27B | 4.07B | 3.83B | 3.66B | 3.09B | 2.36B | 2.16B | 1.89B | 1.62B | 1.49B |
| Research and development | 782.7M | 884.0M | 849.7M | 590.5M | 505.7M | 335.4M | 299.7M | 226.6M | 198.4M | 162.3M |
| Selling, general and administrative | 1.81B | 1.39B | 1.34B | 1.42B | 1.45B | 854.2M | 736.9M | 683.5M | 544.2M | 502.9M |
| Operating income | -430.2M | 716.6M | 578.6M | -65.5M | 170.3M | 378.1M | 532.4M | 614.8M | 528.8M | 591.7M |
| Depreciation and amortization | 41.6M | 32.8M | 30.4M | 30.3M | 26.7M | 18.7M | 15.3M | 15.2M | 13.1M | 11.8M |
| EBITDA | -388.6M | 749.4M | 609.0M | -35.2M | 197.0M | 396.8M | 547.7M | 630.0M | 541.9M | 603.5M |
| Interest expense | 32.8M | 32.8M | 89.9M | 87.6M | 62.5M | 56.7M | 37.8M | 27.5M | ||
| Income before tax | -627.9M | 470.4M | 297.9M | -372.8M | -112.8M | 275.1M | 454.3M | 529.5M | 441.1M | 532.4M |
| Income tax | -272.4M | -91.4M | -119.9M | -158.6M | 216.1M | 33.5M | -73.2M | 80.2M | -47.7M | 135.2M |
| Net income | -356.1M | 560.1M | 414.8M | -224.1M | -329.7M | 238.6M | 523.4M | 447.1M | 487.8M | 396.8M |
| Earnings per share, basic | -5.84 | 9.06 | 6.55 | -3.58 | -5.52 | 4.28 | 9.22 | 7.45 | 8.13 | 6.56 |
| Earnings per share, diluted | -5.84 | 8.65 | 6.10 | -3.58 | -5.52 | 4.22 | 9.09 | 7.30 | 7.96 | 6.41 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.39B | 2.41B | 1.51B | 881.5M | 591.4M | 1.06B | 637.3M | 309.6M | 386.0M | 366.0M |
| Receivables | 830.7M | 716.8M | 705.8M | 651.5M | 563.4M | 396.5M | 356.0M | 263.8M | 224.1M | 234.2M |
| Inventory | 417.0M | 480.4M | 597.0M | 714.1M | 1.07B | 95.4M | 78.6M | 53.0M | 43.2M | 34.1M |
| Current assets | 4.17B | 4.63B | 3.44B | 2.61B | 2.61B | 2.84B | 1.63B | 1.23B | 968.3M | 748.1M |
| Property, plant and equipment | 127.9M | 131.5M | 200.4M | 170.1M | 107.5M | |||||
| Goodwill | 1.83B | 1.72B | 1.75B | 1.69B | 1.83B | 958.3M | 920.0M | 927.6M | 947.5M | 893.8M |
| Total assets | 11.7B | 12.0B | 11.4B | 10.8B | 12.3B | 6.54B | 5.54B | 5.20B | 5.12B | 4.80B |
| Accounts payable | 122.1M | 77.9M | 102.8M | 90.8M | 100.3M | 26.9M | 45.7M | 40.6M | 24.4M | 22.4M |
| Current liabilities | 2.24B | 1.04B | 1.54B | 933.2M | 809.3M | 653.7M | 364.5M | 345.5M | 293.9M | 257.4M |
| Long-term debt | 4.33B | 6.08B | 5.11B | 5.69B | 6.02B | 1.85B | 1.57B | 1.56B | 1.54B | 1.99B |
| Total debt | 5.36B | 6.11B | 5.71B | 5.72B | 6.05B | 2.09B | 1.61B | 1.60B | 1.58B | 2.03B |
| Shareholders' equity | 4.32B | 4.09B | 3.74B | 3.09B | 3.97B | 3.66B | 3.11B | 2.76B | 2.71B | 1.88B |
| Shares outstanding | 61.4M | 60.6M | 62.3M | 63.2M | 61.6M | 56.2M | 56.1M | 57.7M | 58.9M | 59.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.36B | 1.40B | 1.09B | 1.27B | 778.5M | 899.6M | 776.4M | 798.9M | 693.1M | 592.4M |
| Capital spending | -58.8M | -38.1M | -24.0M | -29.0M | -27.6M | -15.0M | -40.1M | -20.4M | -28.9M | -9.69M |
| Free cash flow | 1.30B | 1.36B | 1.07B | 1.24B | 750.9M | 884.6M | 736.3M | 778.5M | 664.1M | 582.7M |
| Cash from investing | -1.51B | -508.2M | -163.1M | -446.2M | -5.21B | -1.01B | -155.3M | -394.5M | -268.9M | -1.75B |
| Cash from financing | -873.4M | 20.5M | -305.3M | -529.5M | 3.97B | 528.1M | -293.7M | -479.1M | -409.1M | 541.0M |
| Share buybacks | -125.0M | -311.4M | -269.8M | -54.0K | 0 | -146.5M | -301.4M | -523.7M | -98.8M | -278.3M |
| Change in cash | -1.02B | 906.6M | 624.8M | 290.0M | -466.3M | 420.4M | 327.7M | -76.4M | 20.1M | -622.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 2, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 2, 2026 | Results | SEC |
| 8-K · Current report | Oct 26, 2026 | Results | SEC |
| 8-K · Current report | Oct 9, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Oct 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 23, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 31, 2026 | Material contract | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 27, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 25, 2026 | Current report | SEC |
| 8-K · Current report | Aug 10, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2026 | Results | SEC |
| 8-K · Current report | Jul 24, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jul 14, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Jun 8, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 8, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 8, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | May 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 29, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Apr 24, 2026 | Annual report | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 26, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 24, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 17, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 8-K · Current report | Oct 28, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 22, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 8, 2025 | Other filings | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Jazz Pharmaceuticals plc’s releases
- Common shares
- 64,914,577
- Fully diluted
- 64,914,577
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 64,914,577 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 64,914,577 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ted W Love Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past) | Director · Since at least Dec 1, 2025 |
| Kathryn Falberg Other companies: Nuvation Bio Inc. (Board of Directors · Since at least Feb 10, 2021); Arcus Biosciences, Inc. (Board Member · Since at least Mar 14, 2018); The Trade Desk, Inc. (Director · Since at least Sep 20, 2016); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Jun 7, 2021 · Past); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Sio Gene Therapies Inc (Director · Apr 7, 2017 – May 15, 2017 · Past); BioMarin Pharmaceutical Inc. (Director · Jul 15, 2016 – Jul 15, 2016 · Past); Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 24, 2016 · Past); Medivation Inc (Director · Jan 31, 2013 – Sep 28, 2016 · Past); Novelion Therapeutics Inc (Director · Mar 25, 2009 – May 26, 2011 · Past); Oruka Therapeutics, Inc. (CFO and COO · Feb 23, 2009 – Jun 25, 2009 · Past); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – May 4, 2016 · Past) | EVP and CFO · Dec 1, 2009 – Mar 5, 2014 · Past |
| Karen Smith Other companies: Context Therapeutics Inc. (Independent Director · Since at least Sep 4, 2024); Skye Bioscience, Inc. (Director · Since at least Jul 2, 2024); Sangamo Therapeutics, Inc. (Director · Since at least Jun 26, 2018); Aurinia Pharmaceuticals Inc (Director · Aug 18, 2023 – Nov 21, 2024 · Past); Quince Therapeutics, Inc. (Chief Medical Officer · May 19, 2022 – Feb 1, 2023 · Past); Tourmaline Bio Inc. (Director · May 16, 2022 – Jun 13, 2023 · Past); Emergent BioSolutions Inc. (EVP, Chief Medical Officer · May 21, 2020 – May 7, 2021 · Past); Antares Pharma Inc (Director · Mar 1, 2019 – May 24, 2022 · Past); Acceleron Pharma Inc (Director · Nov 15, 2017 – Nov 19, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Jul 15, 2017 – Feb 13, 2018 · Past) | EVP, R&D and CMO · Apr 13, 2015 – Mar 5, 2018 · Past |
| Catherine Angell Sohn Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Altimmune, Inc. (Director · Since at least Mar 23, 2023); Axcella Health Inc (Director · Aug 21, 2019 – May 19, 2022 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Palisade Bio, Inc. (Director · Jan 13, 2014 – Jul 1, 2015 · Past); Lifecore Biomedical, Inc. (Director · Nov 13, 2012 – Jun 4, 2022 · Past) | Director · Jul 27, 2012 – Aug 11, 2023 · Past |
| Karen J. Wilson Other companies: Connect Biopharma Holdings Limited (Board Director · Since at least Mar 16, 2026); Serina Therapeutics, Inc. (Director · Since at least Jan 14, 2025); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Elicio Therapeutics, Inc. (Director · Since at least Feb 4, 2021); Vaxart, Inc. (Director · Aug 25, 2020 – Jun 16, 2021 · Past) | SVP, Finance & PAO · Mar 9, 2011 – Mar 5, 2019 · Past |
| Norbert Riedel Other companies: Eton Pharmaceuticals, Inc. (Chairman · Since at least Nov 9, 2018); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); Aptinyx Inc (EXECUTIVE CHAIRMAN OF THE BOD, Director · Jun 20, 2018 – Jan 3, 2023 · Past); Ariad Pharmaceuticals Inc (Director · Apr 28, 2011 – Feb 16, 2017 · Past); Baxter International Inc. (Corporate Vice President · Mar 14, 2006 – Jan 16, 2013 · Past) | Chairperson, Eton Pharmaceuticals, Inc. · Since at least May 2, 2013 |
| Paul L. Berns Other companies: Kardigan, Inc. (Director · Since at least Jun 17, 2026); Metsera, Inc. (Director · Since at least Jan 30, 2025); Neumora Therapeutics, Inc. (See Remarks, Director · Since at least Sep 14, 2023); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Unity Biotechnology Inc (Director · Jun 24, 2021 – Jun 21, 2024 · Past) | Director · Nov 2, 2020 – Aug 5, 2021 · Past |
| Robert Iannone Other companies: Pliant Therapeutics, Inc. (Director · Since at least Jul 9, 2026); Autolus Therapeutics plc (Chair of the Research & Development Committee · Since at least Mar 18, 2026); Iteos Therapeutics Inc (Director · Apr 29, 2021 – Jun 11, 2024 · Past); Jounce Therapeutics Inc (Director · Jan 21, 2020 – May 3, 2023 · Past); Immunomedics Inc (CHIEF MEDICAL OFFICER · Apr 12, 2018 – Mar 14, 2019 · Past) | EVP, Global Head of R&D & CMO · Since at least May 29, 2019 |
| Michael P. Miller Other companies: Rigel Pharmaceuticals, Inc. (Director · Since at least Feb 1, 2026); BioXcel Therapeutics, Inc. (Director · Since at least Jul 1, 2022); Puma Biotechnology Inc (Director · Since at least Feb 23, 2018); VIVUS Inc (Chief Commercial Officer · Apr 26, 2010 – Jan 25, 2013 · Past) | EVP, US Commercial · Jul 31, 2014 – Mar 12, 2020 · Past |
| Renée Galá Other companies: DexCom, Inc. (Director · Since at least Mar 6, 2025); Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 8, 2023 · Past); Corcept Therapeutics Incorporated (Director · Mar 6, 2018 – Aug 20, 2018 · Past); Theravance Biopharma, Inc. (SVP, Chief Financial Officer · Nov 20, 2017 – Nov 20, 2018 · Past) | President & CEO, Director · Since at least Mar 16, 2020 |
All 40 people
| Person | Seat |
|---|---|
| Russell J. Cox Other companies: Gossamer Bio, Inc. (Director · Since at least Feb 7, 2019); Immunic, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 11, 2019 · Past); Spyre Therapeutics, Inc. (Director · Apr 6, 2016 – Jun 22, 2023 · Past) | EVP & COO · Feb 8, 2011 – Dec 11, 2017 · Past |
| Jennifer E. Cook Other companies: BridgeBio Pharma, Inc. (Director · Since at least Jun 21, 2024); Denali Therapeutics Inc. (Director · Since at least May 31, 2024) | Director · Since at least Dec 4, 2023 |
| Kim Sablich Other companies: Eiger Biopharmaceuticals Inc (Director · Apr 23, 2021 – Mar 1, 2023 · Past); Myovant Sciences Ltd (Chief Commercial Officer · Dec 1, 2018 – Apr 3, 2020 · Past) | EVP, GM of U.S. · Jun 1, 2020 – Jun 5, 2023 · Past |
| Mark D. Smith Other companies: Phreesia, Inc. (Board Member · Since at least Jul 17, 2019); Teladoc Health, Inc. (Director · Since at least Oct 22, 2018) | Professor, University of California, San Francisco and Director, Teladoc Health, Inc. and Phreesia, Inc. · Since at least Dec 1, 2020 |
| Matthew Young Other companies: CytomX Therapeutics, Inc. (Director · Since at least Oct 7, 2015); PRA Health Sciences Inc (Director · Feb 9, 2015 – Jul 1, 2021 · Past) | EVP & CFO · Mar 9, 2014 – Mar 5, 2019 · Past |
| Suzanne Sawochka Hooper Other companies: Eidos Therapeutics Inc (Director · Aug 6, 2020 – Jan 26, 2021 · Past); NGM Biopharmaceuticals Inc (Director · Apr 3, 2019 – Apr 5, 2024 · Past) | EVP & General Counsel · Mar 12, 2012 – Feb 25, 2019 · Past |
| Ted W. Love Other companies: Gilead Sciences, Inc. (Director · Since at least May 4, 2026); Royalty Pharma plc (Board Member · Since at least Sep 29, 2025) | Director, Jazz Pharmaceuticals plc · Since at least Nov 5, 2025 |
| Bruce C. Cozadd Other companies: Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past) | Director · Since at least Oct 1, 2020 |
| Michael A DesJardin Other companies: Horizon Pharma PLC (EVP, Technical Operations · Feb 22, 2017 – Feb 20, 2019 · Past) | SVP, Product Development · Feb 8, 2011 – Aug 13, 2011 · Past |
| Neena M Patil Other companies: Teleflex Incorporated (Director · Since at least Apr 29, 2022) | EVP & Chief Legal Officer · Since at least Jul 29, 2019 |
| Patrick G. Enright Other companies: Veradermics, Incorporated (Board Member · Since at least Nov 5, 2026) | Managing Director, Longitude Capital · Since at least Aug 5, 2026 |
| Rick E Winningham Other companies: Theravance Biopharma, Inc. (CHIEF EXECUTIVE OFFICER, Director · Since at least May 20, 2025) | Director · Since at least Aug 7, 2025 |
| Anne ORiordan | Director · Since at least Feb 14, 2019 |
| Carol A Gamble | SVP and General Counsel · Nov 30, 2011 – Mar 9, 2012 · Past |
| Christopher J Tovey | EVP, COO & Managing Director E · May 5, 2022 – Jul 5, 2022 · Past |
| E Alexander Albert | Director · Jul 16, 2008 – Aug 15, 2008 · Past |
| Elmar Schnee | Director · Aug 1, 2014 – Aug 5, 2021 · Past |
| Finbar Larkin | SVP, Technical Operations · Oct 31, 2019 – Mar 3, 2023 · Past |
| Heather Ann McSharry | Director, International Airlines Group · Since at least Aug 7, 2025 |
| Janne LT Wissel | SVP, Chief Regulatory Officer · May 31, 2007 – May 31, 2011 · Past |
| Laura Hamill | Director · Since at least Aug 5, 2026 |
| Mary Elizabeth Henderson | SVP, Technical Operations · Since at least Aug 3, 2023 |
| Patricia Carr | SVP, Chief Accounting Officer · Since at least Aug 7, 2019 |
| Patrick Kennedy | Director, Jazz Pharmaceuticals plc · Since at least Mar 1, 2024 |
| Paul Treacy | SVP, Technical Operations · Jul 31, 2014 – Aug 12, 2019 · Past |
| Rick E Winningham | Lead Independent Director, Jazz Pharmaceuticals plc · Since at least Jul 10, 2025 |
| Robert M Myers | President, Director · May 28, 2010 – Nov 30, 2010 · Past |
| Samantha Pearce | EVP, Chief Commercial Officer · Since at least Jan 17, 2024 |
| Seamus Mulligan | Director, Jazz Pharmaceuticals plc · Since at least Aug 5, 2022 |
| Thomas Riga | Chief Business Officer · Since at least Jan 8, 2026 |
Log in to ask 6ix AI your own questions about Jazz Pharmaceuticals plc.